13666-71-2 Usage
General Description
2-AMINO-N-(3-MORPHOLIN-4-YLPROPYL)BENZAMIDE is a chemical compound consisting of a benzamide group with an attached 3-morpholin-4-ylpropyl moiety. 2-AMINO-N-(3-MORPHOLIN-4-YLPROPYL)BENZAMIDE has a primary amine group attached to the benzamide, making it a potential candidate for various biological and pharmaceutical applications. It is a derivative of benzamide, which is known for its pharmaceutical properties and is often used as a building block for the synthesis of various drugs. The presence of the morpholine group in the compound suggests potential interactions with biological systems, making it a promising compound for further research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 13666-71-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,6,6 and 6 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 13666-71:
(7*1)+(6*3)+(5*6)+(4*6)+(3*6)+(2*7)+(1*1)=112
112 % 10 = 2
So 13666-71-2 is a valid CAS Registry Number.
InChI:InChI=1/C14H21N3O2/c15-13-5-2-1-4-12(13)14(18)16-6-3-7-17-8-10-19-11-9-17/h1-2,4-5H,3,6-11,15H2,(H,16,18)
13666-71-2Relevant articles and documents
Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase
Li, Yang,Ganesh, Thota,Diebold, Becky A,Zhu, Yerun,McCoy, James W,Smith, Susan M. E,Sun, Aiming,Lambeth, J. David
supporting information, p. 1047 - 1052 (2015/10/20)
Myeloperoxidase (MPO) is a key antimicrobial enzyme, playing a normal role in host defense, but also contributing to inflammatory conditions including neuroinflammatory diseases such as Parkinsons and Alzheimers. We synthesized and characterized more than 50 quinazolin-4(1H)-one derivatives and showed that this class of compounds inhibits MPO with IC50 values as low as 100 nM. Representative compounds showed partially reversible inhibition that was competitive with respect to Amplex Red substrate and did not result in the accumulation of MPO Compound II. Members of this group show promise for therapeutic development for the treatment of diseases in which inflammation plays a pathogenic role.
